Results 1 to 10 of about 30,982 (215)

Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line

Current Issues in Molecular Biology, 2022
Preclinical studies of COVID-19 mRNA vaccine BNT162b2, developed by Pfizer and BioNTech, showed reversible hepatic effects in animals that received the BNT162b2 injection.
Yang De Marinis, Magnus Rasmussen, Markus Aldén   +2 more
exaly   +5 more sources

Anti-PEG Antibodies From mRNA COVID-19 Vaccines Affect In Vitro Measurements of Pegylated Drug Levels. [PDF]

Clin Transl Sci
ABSTRACT The recent adoption of mRNA‐based technology for vaccine development has led to widespread exposure to new vaccine components, such as polyethylene glycol (PEG), against which antibodies may be made. This study assesses the presence of anti‐PEG antibodies in human serum following SARS‐CoV‐2 vaccination, and if these antibodies could interfere ...
Svyatova EA, Liu Z, Becker RE, Sung JM, Fayomi AP, Florian JA, Weaver JL, Rouse R, Howard KE.   +8 more
europepmc   +2 more sources

SARS-CoV-2 mRNA Vaccination Induces Neutralizing Antibodies and Type I IFN Changes in People Living With HIV. [PDF]

J Med Virol
ABSTRACT This study examined changes in anti‐Spike (anti‐S) antibodies (Abs) and type I interferon (IFN‐I) following the BNT162b2 vaccine in people living with HIV (PLWH) and analyzed the impact of demographic and immunological factors. In total, 75 PLWH and 28 healthy donors were followed at baseline (T0), at the second dose (T1), after the second ...
Frasca F, Maddaloni L, D'Auria A, Fracella M, Bugani G, Falvino C, Baccolini V, Migliara G, Aloisi F, Santinelli L, Palermo E, Bortolani L, Lazzaro A, Ceccarelli G, Turriziani O, Mastroianni CM, Antonelli G, d'Ettorre G, Scagnolari C.   +18 more
europepmc   +2 more sources

Immunogenicity, Tolerability, and Safety of BA.1-Adapted BNT162b2 Vaccine in 18- to 55-Year-Olds Previously Vaccinated with BNT162b2 or Who Were COVID-19 Vaccine-Naive [PDF]

Infectious Diseases and Therapy
Introduction Variant-adapted COVID-19 vaccines can induce more robust immune responses against closely matched circulating variants than original vaccines.
David Fitz-Patrick, Omair Sahgal, Leon F. Fouché, Essack Mitha, Mookho Malahleha, Juleen Gayed, Georgina Keep, Ying Zhang, Kayvon Modjarrad, Todd Belanger, Xia Xu, David Cooper, Federico J. Mensa, Uǧur Sahin, Ӧzlem Türeci, Kena A. Swanson, Annaliesa S. Anderson, Alejandra Gurtman, Nicholas Kitchin   +18 more
doaj   +2 more sources

Longitudinal Dynamics of SARS-CoV-2 IgG Antibody Responses after the Two-Dose Regimen of BNT162b2 Vaccination and the Effect of a Third Dose on Healthcare Workers in Japan

Vaccines, 2022
Analysis of longitudinal dynamics of humoral immune responses to the BNT162b2 COVID-19 vaccine might provide useful information to predict the effectiveness of BNT162b2 in preventing SARS-CoV-2 infection.
Shigeki Nabeshima, Kazunari Ishii, Ryo Ozuru   +2 more
exaly   +3 more sources

A Study to Investigate the Safety and Immunogenicity of Monovalent Omicron LP.8.1-Adapted BNT162b2 COVID-19 Vaccine in Adults ≥ 65 Years of Age and High-Risk Adults 18–64 Years of Age (Preliminary Results) [PDF]

Vaccines
Background/Objectives: This study evaluated the Omicron LP.8.1 variant-adapted BNT162b2 mRNA vaccine (LP.8.1-adapted BNT162b2). Methods: This analysis is part of an ongoing phase 3 open-label study evaluating the immunogenicity, safety, and tolerability ...
Rucha Dadhe, Juleen Gayed, Muneeb Iqbal, Rohit Solan, Han Wu, Hua Ma, Xia Xu, Federico J. Mensa, Todd Belanger, David Cooper, Robin Mogg, Annaliesa S. Anderson, Özlem Türeci, Uǧur Şahin, Pirada Suphaphiphat Allen, Kayvon Modjarrad, Alejandra Gurtman, Kelly Lindert   +17 more
doaj   +2 more sources

Effectiveness of a third dose of COVID-19 vaccines against delta variant of SARS-COV-2: A Serbian cohort study [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2023
Introduction/Objective. The duration of vaccine-induced protection against SARS-CoV-2 is shown to be limited. The aim of this study was to assess vaccine effectiveness (VE) of a third dose of four different COVID-19 vaccines during Delta variant ...
Đorđević Nataša, Matić Sanja, Milovanović Dragan, Stefanović Srđan, Popović Suzana, Todorović Danijela, Đurđević Predrag, Sazdanović Predrag, Antić Vasilije, Lončar Slavica, Bukumira Slavica, Radenković Marko, Šusteršić Tijana, Filipović Nenad, Baskić Dejan   +14 more
doaj   +1 more source

Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines

Human Vaccines & Immunotherapeutics, 2023
Introduction of primary COVID-19 vaccination has helped reduce severe disease and death caused by SARS-CoV-2 infection. Understanding the protection conferred by heterologous booster regimens informs alternative vaccination strategies that enable ...
Moe H. Kyaw, Julia Spinardi, Ling Zhang, Helen May Lin Oh, Amit Srivastava   +4 more
doaj   +1 more source

SARS-CoV-2 Antibody Dynamics in Healthcare Workers after mRNA Vaccination

Vaccines, 2023
Since the emergence of SARS-CoV-2, maintaining healthcare worker (HCW) health and safety has been fundamental to responding to the global pandemic. Vaccination with mRNA-base vaccines targeting SARS-CoV-2 spike protein has emerged as a key strategy in ...
Kevin D. Dieckhaus, Min-Jung Kim, Jian-Bing Shen, Tina S. Liang, Michael J. Kleinberg, Kristen M. Siedlarz, David B. Banach, Mark L. Metersky, Rob P. Fuller, Eric M. Mortensen, Bruce T. Liang   +10 more
doaj   +1 more source

Granulomatous anterior uveitis following mRNA-based COVID-19 vaccination: A case report

Indian Journal of Ophthalmology, 2023
A 23-year-old patient presented with complaints of redness, pain, photophobia, and blurred vision in the right eye 15 days after she received the third dose of BNT162b2 vaccination.
Furkan Cam, Gizem Gok, Hande Celiker
doaj   +1 more source